A Phase 1-2 Multi-Center Study Evaluating KTE-C19 in Subjects With Refractory Aggressive Non-Hodgkin Lymphoma (ZUMA-1) (ZUMA-1)This is a single arm, open-label, multi-center, phase 1/2 study, to determine the safety and efficacy of KTE-C19, an autologous anti-CD19 chimeric antigen receptor (CAR)-positive T cell therapy, in refractory aggressive Non-Hodgkin Lymphoma (NHL). Recruiting Principal Investigator Kevin SongBody Locations and Systems Immune System and DisordersArea VancouverAge 18 and above
Lymphoid Cancers Families StudyLymphocyte cancers are the fourth most common cancer in both men and women. Research into the genetics and environmental factors contributing to lymphoid cancers is an important step to prevent and/or control these cancers. Multiple diagnoses of lymphoid cancer within the same family may indicaRecruiting Principal Investigator Angela Brooks-WilsonArea Vancouver
CLIC-1901 for the Treatment of Patients With Relapsed/Refractory CD19 Positive Hematologic Malignancies (CLIC-01)The purpose of this study is to evaluate the safety, feasibility and efficacy of CLIC-1901 autologous anti-CD19 Chimeric Antigen Receptor T cells (CAR-T) cells for participants with relapsed/refractory CD19 positive (CD19+) Acute Lymphoblastic Leukemia (ALL) and non-Hodgkin's Lymphoma (NHL). Recruiting Principal Investigator Kevin HayBody Locations and Systems LeukemiaArea VancouverAge 18-75
A Study to Evaluate a Therapeutic Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seropositive Recipients Undergoing Allogeneic, Hematopoietic Cell Transplant (HCT) (HELIOS)The purpose of the study is to determine if overall mortality is affected one year after a hematopoietic stem cell transplant (HCT) in patients given a vaccine to prevent cytomegalovirus (CMV). Safety of ASP0113 in subjects undergoing allogeneic HCT will also be evaluated. Closed for Recruitment Principal Investigator Raewyn BroadyBody Locations and Systems LeukemiaArea VancouverAge 18 and above
A Drug Study in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)The purpose of this study is to assess the efficacy of ruxolitinib against best available therapy in participants with steroid-refractory chronic graft-versus-host disease (SR cGvHD). Closed for Recruitment Principal Investigator Raewyn BroadyBody Locations and Systems LeukemiaArea VancouverAge 12 and above
A Study Evaluating the Efficacy of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Subjects With Relapsed/Refractory Diffuse Large…The purpose of this study is to evaluate whether axicabtagene ciloleucel therapy improves the clinical outcome compared with standard of care second-line therapy in patients with relapsed/refractory Diffuse Large B Cell Lymphoma. Closed for Recruitment Principal Investigator Kevin SongBody Locations and Systems BloodArea VancouverAge 18 and above
